Publications by authors named "Curt Hartleben-Matkin"
Introduction: Cystoid macular edema (CME) presents with thickening of the macula with an accumulation of fluid due to breakage of the inner and outer blood-retinal barriers. It is referred to as pseudophakic CME (PCME) if it occurs after cataract surgery. PGF2a is a prostaglandin analog (PGA) used to lower intraocular pressure (IOP).
View Article and Find Full Text PDFBackground/purpose: Identify the prevalence and risk factors for secondary glaucoma among Mexican-mestizo patients with Vogt-Koyanagi-Harada Disease (VKH).
Methods: Retrospective cohort study analyzing the demographic, clinical, and epidemiological variables. Risk estimates were calculated using a Cox proportional hazards regression model.
Article Synopsis
- The study aimed to assess how common secondary glaucoma is in patients with Vogt-Koyanagi-Harada (VKH) disease, along with its clinical features and underlying mechanisms.
- An analysis of 305 eyes from 155 patients revealed that 22% developed secondary glaucoma, particularly in those with chronic recurrent VKH, with angle-closure being a major factor.
- The findings indicated that patients with glaucoma had worse visual acuity compared to those without, highlighting the serious impact of glaucoma in VKH-related eye conditions.
Article Synopsis
- Primary angle closure glaucoma (PACG) is a key cause of blindness, prompting a large-scale study involving over 10,000 PACG patients and nearly 30,000 controls across multiple continents.
- The study identified five new genetic loci associated with PACG risk, each with significant statistical results (e.g., EPDR1 with an odds ratio of 1.24 and a P-value of 5.94 × 10(-15)).
- Additionally, three previously known genetic loci were confirmed, enhancing the understanding of the genetic factors underlying PACG.
Background: There are different etiologies related to glaucoma, with the involvement of different systems in the origin and development of the disease.
Methods: We performed a literature review.
Results: The data is divided, with an emphasis on five main topics: systemic disease, neurodegenerative disease, genetic disease, immunological disease, and aging of the trabecular meshwork.
Aim: To evaluate the long-term response to the fixed combination of dorzolamide/timolol in patients with primary open angle glaucoma (POAG) and the addition of other intraocular pressure (IOP) lowering medications such as prostaglandin analogs and brimonidine.
Methods: A retrospective, non-randomized, and descriptive clinical study was performed with 182 eyes diagnosed with POAG. Patients were divided into three groups: a group with fixed combination of dorzolamide/timolol only, a second group with prostaglandin analogs plus fixed combination of dorzolamide/timolol, and a third group with the addition of brimonidine to the same fixed combination.
The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
Ann Ophthalmol (Skokie)
April 2010
We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.
View Article and Find Full Text PDF